Research programme: anti-CA19-9 monoclonal antibody - Quest PharmaTechAlternative Names: Anti-CA19.9 monoclonal antibody - Quest PharmaTech; AR44.6; GivaRex
Latest Information Update: 06 Mar 2014
At a glance
- Originator ViRexx Medical Corp
- Developer Quest PharmaTech
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer